| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 93 | 7.7x | 17.8x | Top tier | |
Growth | 85 | 6.9% | 7.1% | Top tier | |
Quality | 95 | 75.9% | 4.5% | Top tier | |
Safety | 83 | — | 2.6x | Top tier | |
Capital Return | 69 | — | 2.12% | Top tier | |
Momentum | 94 | 77.9% | 2.9% | Top tier | |
Sentiment | 64 | 3 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Nutex Health operates a network of scalable micro-hospitals and generates most of its revenue from emergency, observation, inpatient, diagnostic, and therapeutic services. It also operates a population health division comprising independent physician associations in Southern California, Houston, Phoenix, and South Florida, overseeing approximately 40 thousand patients enrolled in Medicare Advantage, commercial insurance, and managed Medicaid programs. Its growth strategy relies on increasing patient visits and case complexity, adding services such as colonoscopy and upper diagnostic endoscopy, and opening three to five hospitals annually.
In Q2 fiscal 2026, revenue was $210.8 million, down 13.6% from $244 million in the comparable period, while gross profit rose 15.8% to $141.3 million and gross margin increased to 67% from 51.2%. The company recorded net income of $65.8 million and earnings per share of $9.38, compared with a net loss of $17.7 million in the comparable period, while operating income reached $121.7 million and adjusted earnings before interest, taxes, depreciation, and amortization reached $90 million.
The hospital segment accounted for $201.9 million, or approximately 95.8% of Q2 fiscal 2026 revenue, despite a 14.6% decline in its revenue, while population health revenue rose 16% to $8.9 million. Hospital visits increased 9.6% to 49,962 visits, and same-hospital visits grew 6.3%. On a trailing twelve-month basis, revenue was $880 million, net income was $96.4 million, and earnings per share were approximately $13.42.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” with an average price target of $310 and identical high and low targets of $310. This target is approximately 52% above the upper end of the 52-week range of $204, but it lacks dispersion that would illustrate differences among analyst scenarios. No published price-to-earnings ratio is available, so the optimistic target should be weighed against the Q2 fiscal 2026 revenue decline and the fact that the earnings improvement depended partly on substantial reductions in contract costs and stock-based compensation.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
Nutex Health generated net income of approximately $65.8 million in Q2 fiscal 2026, compared with a net loss of $17.7 million in the comparable period. Gross profit increased to $141.3 million with a margin of 67%, while operating income reached $121.7 million. The HaloMD amendment contributed approximately $48 million in reduced contract services expense, and stock-based compensation declined to $2.9 million from $78.7 million.
Q2 fiscal 2026 revenue declined 13.6% to $210.8 million, while hospital visits increased 9.6% to 49,962. Management explained that the 2025 comparison period benefited from an increase in the estimated collection rate from 65% as of December 31, 2024 to 75% as of June 30, 2025, resulting in substantial positive revenue adjustments. After the historical collection rate stabilized at slightly above 80%, revenue per visit moved closer to the cumulative range of $4,000 to $4,200 since the dispute resolution process began in July 2024.
Nutex Health submits between 50% and 60% of its claims to the independent dispute resolution process and wins more than 85% of decisions. Average collection on favorable decisions exceeds 80%, but management said in August 2026 that improvement in in-network contracts remained slight and not material. The federal rule reduced the CMS fee from $115 to $15 per party for disputes initiated on or after June 11, 2026, reducing the cost of using the process.
The company expects to open hospitals in West Little Rock, San Antonio, and Jacksonville during Q3 and Q4 fiscal 2026. The 2027 plan includes projects in South, Central, and East Florida and in Oklahoma, with Nutex Health initially owning and developing two of them. Management confirmed on August 7, 2026 that its operating target remained three to five hospital openings annually.
Cash and cash equivalents totaled $205.2 million as of June 30, 2026, an increase of $19.6 million from December 31, 2025. Net cash flow from operating activities was $109.7 million in the first half of fiscal 2026, up approximately 40% from $78.2 million in the comparable period. At the same time, bank and equipment debt declined to $39.9 million, with most of it related to hospital equipment such as MRI, X-ray, ultrasound, and CT machines.
The analyst target is $310, which is also both the high and low estimate, while the 52-week range is $77.21 to $204. The uniform target is approximately 52% above the top of that range, making it an optimistic assumption that does not show variation among valuation scenarios. No published price-to-earnings ratio is available, while Q2 fiscal 2026 revenue declined 13.6% and earnings benefited from substantial reductions in HaloMD costs and stock-based compensation.
